What question did this study set out to answer?

The aim is to evaluate the real-world effectiveness and safety of Upadacitinib in Korean patients with Crohn’s disease and ulcerative colitis.

P0829Effectiveness and Safety of Upadacitinib in Patients with Crohn’s Disease and Ulcerative Colitis: a Korea Multicenter Retrospective Cohort Study

View Full Paper

Ask AI

Bookmark

The aim is to evaluate the real-world effectiveness and safety of Upadacitinib in Korean patients with Crohn’s disease and ulcerative colitis.
Conducted a retrospective study across three Korean academic centers.
Analyzed data from 79 patients treated with Upadacitinib, divided into UC (n=30) and CD (n=49).
Assess clinical, biochemical, and endoscopic outcomes at specified weeks for both conditions.
In UC, substantial improvements noted by week 16, including partial Mayo score reduction to 2 and endoscopic subscore to 0.
In CD, CDAI improved to 80.3 by week 12.
The Upadacitinib continuation rate was 96.7% for UC and 83.6% for CD, indicating strong effectiveness.
Most frequent adverse events included acne, lymphopenia, anemia, herpes zoster, and infections, with no serious complications.

No takes yet. Share an insight, caveat, or question.

Multicenter retrospective cohort study shows Upadacitinib improves outcomes in Korean patients with IBD, suggesting its effectiveness.

Lee et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark